Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

Kiora Pharmaceuticals, Inc.

eyegatepharma.com
Filed: Mar 25, 2026ENCINITAS, CACIK: 0001372514Healthcare
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Kiora Pharmaceuticals announced its 2025 financial results and clinical development progress on March 25, 2026, providing investors with updates on operational performance and strategic direction in the biopharmaceutical sector.

Key Takeaways

Company reported financial results for the year ended December 31, 2025, indicating completed fiscal year performance review

Clinical development milestones were achieved and communicated as part of the company's strategic progress

2 more takeaways

Related Filings (2)

2 more filings from Kiora Pharmaceuticals, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateMar 25, 2026
Item2.02
CategoryFinancial Results
CIK0001372514
Accession #kprx-20260325
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earningsproduct launch

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings